Global Life Science Business Partnering (GLSBP) - October 2025

Highlights of Deals in October – 2025

 

Acquisitions:

  1. Halozyme buys subcutaneous drug delivery peer Elektrofi in a deal valued ~US$900 Million.
  2. Denmark’s Novo Nordisk announced that it has entered into a definitive agreement to acquire US clinical-stage liver disease focused biotech Akero Therapeutics.

 

Licensing:

1.     Cipla has in-licensed tirzepatide (Yurpeak) from Eli Lilly for India. The deal positions Cipla as a first mover in India's nascent GLP-1 obesity care segment, projected to grow 40x by 2030.

2.     Biocon Biologics out-licenses Insulin Glargine to Civica for commercialization in the US.

3.     MEDINET Japan and Stempeutics India sign option license agreement for Stempeucel in Japan.

4.     Healthium partners with US-based Tisgenx to bring cardiac innovations to India.

5.     AviadoBio to pay up to US$413 million for UgeneX gene therapy rights.

6.     Chicago biotech EVOQ pens US$500M autoimmune pact with Sanofi.

7.     Zenas inks license agreement with InnoCare for 3 autoimmune programs.

8.     Sanofi inks pact with Canadian tech company BenchSci to bring AI to preclinical R&D.

 

Investments:

  1. Expedition raises US$165 million to advance COPD drug licensed from Fosun.
  2. Oura raises US$900M series E as smart ring sales catapult company's growth.
  3. Peptilogics raises US$78M for prosthetic joint infection program.

 

Co-development:

  1. AstraZeneca inks US$555 million deal with Algen.
  2. Arbor partners with Chiesi Group in gene editing deal with potential US$2B future payments.

 

Aagami Updates:

1.     New Client Win: An ASX-listed company from Australia has engaged Aagami to establish Licensing/ Distribution partnership in India and other regions, for its marketed Povidone-Iodine Nasal Spray (Nasodine®). The product was commercially launched in Singapore in 2024, achieving high adoption in hospitals and strong retail traction.

2.     Asia Partnering Success: Completed productive engagements at Asia Bio Singapore, BioJapan, BIOPLUS-INTERPHEX KOREA, with over 50 strategic meetings with potential clients and also buy-side companies. A new client win for Aagami, and several avenues opened up for its clients, making these event participation grand success.

3.     Bio Europe 2025: Aagami’s Vice President, Godwyn Francis, will be attending Bio Europe (November 3–5, 2025), 30+ one-on-one strategic meetings with decision makers already scheduled.

4.     Aagami is also all set to participate in JP Morgan Healthcare Week and BIOTECH SHOWCASE | Jan 12-14, 2026 | San Francisco.

 

Select opportunities available with us:

For Partnering/Licensing/ Co-development:

  1. Seeking Licensing / Distribution Partners: Marketed Povidone-Iodine Nasal Spray (Nasodine®), patented, clinically proven to eliminate respiratory viruses and bacteria, offering safe and effective relief from cold, flu, and nasal congestion. Commercially launched in Singapore (2024) with all government hospitals adoption and strong retail traction; Offering an attractive ready-to-launch OTC opportunity in multiple markets, such as India (except Singapore, Brunei, Malaysia and the Philippines).

2.     US Licensing: FDA Approved Patented Lidocaine Patch using proprietary technology.

3.     Seeking Co-development Partner/Investor/EPO supplier for Phase 3 stage Erythropoietin (EPO) patented asset for Resuscitation from Sudden Cardiac Arrest (A groundbreaking approach).  By using the 351(A) dossier, an easy and quick path via 351 (K) Biosimilar approval for multiple indications may also be obtained.

4.     Seeking Co-development/Out-Licensing: Phase 3 stage small molecule first-in-class eye drop to treat pre-surgical cataract (typically for patients under 72 years of age).

  1. Seeking Out-licensing: Uncoupling Metastasis and Proliferation with translational platform, using Machine Learning and known molecules to disrupt cancer treatment. Lead asset (Phase 2) and platform, both available for licensing.

6.     Seeking Licensing/Partnering: Phase 2 Drug poised to revolutionize antiviral treatment; could be a single drug to treat all the "tripledemic" viruses (RSV, FLU, COVID). Also, Phase 2 trials are starting in Central Africa for MPOX. Very effective in Bird Flu and Measles too.

7.     Dental gel (Marketed in the US & approved in EU) for Prevention & Treatment of Periodontitis, Gingivitis, & Caries. Featured in WSJ, FOX, NBC, ABC, GQ. Already a profit-making product. Licensing available.

 

For Acquisition:

1.    A High Multiple ROI by acquiring small molecule clinical asset in rare diseases (sickle cell disease & thalassemia). (Two Phase 1 completed. Phase 2 ready). Low cost and quicker to market vs. Gene Therapy. Their previous asset was acquired for US$400 million.

2.    Lucrative Opportunity to acquire IP Portfolio (bankruptcy disposition) of clinical stage First-in-Class Non-Opioid Analgesic.

3.    Available at a very reasonable price Mountain View Pharma (MVP) including its PharmaPEG® technology, product candidates, data package of ~20 drug candidates, IP etc. - for Next-generation biologics.


For Investment:

1.     High ROI Opportunity to Invest in U.S.based medtech revolutionizing medical imaging with the world’s first portable, single-sided MRI platform (On the market). With over US$90 million raised in current round, our client is offering special terms to invest in current B-4/B-5 round. Expected ROI is 2-4x in 12-18 months via an IPO, strategic M&A, or private equity buyout.

  1. Seeking Investment: Revolutionizing oncology with patented smart drug delivery platform that enhances chemotherapy efficacy while minimizing toxic side effects. Backed by US$14 million in funding and a team with 7 prior drug launches, client is advancing a pipeline of 5 chemotherapies toward IND. Targeting a US$180 billion+ oncology market.

Hope you found the content useful. We welcome your feedback and queries.

×
Twitter